RARA CRAFT DATABASE for FDA Medical Devices
510(k)K223083

FDA DEVICE FACTS

Straumann SLActive labeling changes

Institut Straumann AG

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEJune 22, 2023PRODUCT CODEDZE

Indications for use

Straumann® BLX Dental Implants, SLActive® Straumann® dental implants are indicated for functional and esthetic oral rehabilitation of the upper or lower jaw of edentulous or partially edentulous patients. K223083 – Traditional 510(k) Straumann® SLActive® Labeling Changes Straumann USA, LLC June 21, 2023 They can be used for immediate, early or late implantation following the extraction or loss of natural teeth. The implants can be placed with immediate function for single-tooth and/or multiple-tooth restorations when good primary stability is achieved and with appropriate occlusal loading to restore chewing function. Straumann® TLX Dental Implants, SLActive® Straumann® dental implants are indicated for the functional and esthetic oral rehabilitation of the upper or lower jaw of edentulous or partially edentulous patients. They can be used for immediate, early or late implantation following the extraction or loss of natural teeth. The implants can be placed wi th immediate function for single- tooth and/or multiple- tooth restorations when good primary stability is achieved and with appropriate occlusal loading to restore chewing function. Other Straumann ® Tissue Level and Bone Level Dental Implants, SLActive® Straumann® dental implants are indicated for functional and esthetic oral rehabilitation of the upper or lower jaw of edentulous or partially edentulous patients. Unless stated in specific indications, they can be used for immediate, early or late implantati on following the extraction or loss of natural teeth. The implants can be placed with immediate function for single-tooth and/or multiple-tooth restorations when good primary stability is achieved and with appropriate occlusal loading to restore chewing function. Specific indications for use Straumann® Roxolid® Bone Level Tapered Implant ∅ 2.9 mm The Straumann® Roxolid® Bone Level Tapered implants ∅ 2.9 mm are indicated for single- unit reconstruction of incisors in the lower jaw and lateral incisors in the upper jaw. Straumann® Roxolid® Standard Plus 4 mm Short Implants Straumann® Roxolid® Standard Plus 4 mm Short Implants are indicated for fixed or removable reconstruction in situations of moderate to severely atrophic jawbone with adequate bone quality that allows primary stability after implant insertion, where a longer implant cannot be placed due to limited vertical bone height. The recommended healing time before loading is between 10 to 12 weeks. Straumann ® Roxolid® Standard Plus 4 mm Short Implants are specifically indicated for: Fixed denture prosthesis/splinted units (one implant per unit). K223083 – Traditional 510(k) Straumann® SLActive® Labeling Changes Straumann USA, LLC June 21, 2023 Pontic cases in combination with at least one longer implant. Fully edentulous cases with at least one Straumann® Roxolid® Standard Plus 4 mm Short Implants in combination with 2 longer implants in the anterior region and at least four total implants. Titanium ∅ 3.3 mm implants ∅3.3 mm S and SP RN implants are to be used only for the following indications: Partially dentate jaws with implant-borne, fixed constructions: combine with a ∅4.1 mm implants and splint the superstructure.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 18, 2026